ASMI welcomes Expert Panel Report
The Australian Self Medication Industry (ASMI) today welcomed the Stage Two Expert Panel report on the regulatory framework for medicines and medical devices.
ASMI Chief Executive Officer, Deon Schoombie, said: "ASMI supports the majority of the Expert Panel's recommendations on the regulation of complementary medicines and therapeutic goods advertising.
"We are pleased the Panel recommended a risk-based approach to regulation and accepted many of the proposals industry put forward in its submissions to address the acknowledged shortcomings in the current system. We look forward to participating in the development of reforms coming out of these recommendations.
"We reserve judgement about the Panel's recommendations on complaints handling and pre-vetting of advertisements as these two areas are highly complex, involve several inter-connected systems and will require a suite of additional reforms. We will consult broadly with stakeholders about these recommended reforms to ensure the most effective systems are implemented.
"We disagree with the Panel's recommendation to retain restrictions on the advertising of Schedule 3 medicines and will continue our advocacy for S3 advertising reforms," he added.